{"id":42562,"date":"2025-10-18T17:45:50","date_gmt":"2025-10-18T12:15:50","guid":{"rendered":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/10\/18\/cupid-limited-achieves-ce-eu-ivdr-certification-for-pregnancy-and-syphilis-test-kits-paving-the-way-for-global-expansion-in-the-multibillion-us-dollar-ivd-market\/"},"modified":"2025-10-18T17:45:50","modified_gmt":"2025-10-18T12:15:50","slug":"cupid-limited-achieves-ce-eu-ivdr-certification-for-pregnancy-and-syphilis-test-kits-paving-the-way-for-global-expansion-in-the-multibillion-us-dollar-ivd-market","status":"publish","type":"post","link":"https:\/\/dailynewsindia.co.in\/index.php\/2025\/10\/18\/cupid-limited-achieves-ce-eu-ivdr-certification-for-pregnancy-and-syphilis-test-kits-paving-the-way-for-global-expansion-in-the-multibillion-us-dollar-ivd-market\/","title":{"rendered":"Cupid Limited Achieves CE (EU IVDR) Certification for Pregnancy And Syphilis Test Kits, Paving the Way for Global Expansion in The Multibillion US Dollar IVD Market"},"content":{"rendered":"
\n

Mumbai (Maharashtra) [India], October 18: Cupid Limited, (BSE \u2013 530843, NSE \u2013 CUPID), <\/strong>Cupid Limited, a leading Indian healthcare and diagnostics manufacturer, announced today that it has been granted CE (EU IVDR) Certification for two of its key in-vitro diagnostic (IVD) devices \u2014 the CupiSURE Pregnancy (hCG) Test Kit and the CupiKIT Syphilis Antibody Test Kit.<\/p>\n

These certifications confirm compliance with the European Union Regulation (EU) 2017\/746 (IVDR), authorizing Cupid to distribute these kits across the European Economic Area and other CE-recognized global markets. The development marks a major step in Cupid\u2019s transition from an Indian healthcare exporter to a globally certified IVD solutions provider.<\/p>\n

Strong Global Market Outlook<\/strong><\/p>\n

Cupid\u2019s certified IVD kits target two of the fastest-growing diagnostic categories:<\/p>\n

Pregnancy (hCG) Test Kits<\/strong>\u00a0\u2014 Global market valued at USD 1.7 billion in 2024, projected to reach USD 2.9 billion by 2034 (CAGR ~5.4%).<\/p>\n

Syphilis Immunoassay Diagnostics\u00a0<\/strong>\u2014 Estimated at USD 611 million in 2025, expected to grow to USD 993 million by 2034 (CAGR ~5.6%).<\/p>\n

In addition, Cupid is in the final stages of securing CE (EU IVDR) Certification for its HIV 1 & 2 Antibody and Hepatitis B Antigen IVD kits, expected by December 2025 \u2014 products that address some of the world\u2019s largest and most urgent diagnostic markets:<\/p>\n

HIV 1 & 2 Antibody Diagnostics<\/strong>\u00a0\u2014 Global market estimated at USD 3.6 billion in 2025, projected to expand to USD 6.1 billion by 2030 (CAGR ~10.7%).<\/p>\n

Hepatitis B Antigen IVD Diagnostics<\/strong>\u00a0\u2014 Valued at USD 1.3 billion in 2024, expected to surpass USD 2.0 billion by 2033 (CAGR ~4.2%).<\/p>\n

Collectively, these four segments represent a vast global market opportunity, offering substantial room for Cupid\u2019s expansion in both public health and private clinical sectors.<\/p>\n

Strategic Significance for Cupid Ltd.<\/strong><\/p>\n

With these CE (EU IVDR) approvals, Cupid can now:<\/p>\n

Participate in European, African, and Latin American tenders for maternal health, STD, and infectious-disease screening.<\/p>\n

Leverage its low-cost, high-quality manufacturing base in India to deliver competitively priced global IVD solutions.<\/p>\n

The certifications also reinforce Cupid\u2019s commitment to diversifying beyond sexual-health products into the broader preventive and diagnostic healthcare space, aligning with the global shift toward early detection and rapid testing.<\/p>\n

Commenting on the Development, Mr. Aditya Kumar Halwasiya, Chairman and Managing Director said, \u201cThe CE (EU IVDR) Certification for our Pregnancy and Syphilis Antibody IVD kits is a milestone achievement that validates Cupid\u2019s global quality standards and technical excellence. These certifications open up huge opportunities for us across Europe, Africa, and Asia. With HIV 1&2 Antibody and Hepatitis B Antigen kits on track for approval by December 2025, Cupid is poised to become one of India\u2019s few integrated diagnostic companies with a globally certified product suite. We aim to build a strong international footprint and make accurate, affordable diagnostics accessible to all.\u201d<\/p>\n

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mumbai (Maharashtra) [India], October 18: Cupid Limited, (BSE \u2013 530843, NSE \u2013 CUPID), Cupid Limited, a leading Indian healthcare and diagnostics manufacturer, announced today that it has been granted CE (EU IVDR) Certification for two of its key in-vitro diagnostic (IVD) devices \u2014 the CupiSURE Pregnancy (hCG) Test Kit and the CupiKIT Syphilis Antibody Test…<\/p>\n

Read More “Cupid Limited Achieves CE (EU IVDR) Certification for Pregnancy And Syphilis Test Kits, Paving the Way for Global Expansion in The Multibillion US Dollar IVD Market”<\/span> »<\/a><\/p>\n","protected":false},"author":1,"featured_media":42563,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[636,640],"class_list":["post-42562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-pr","tag-press-release"],"_links":{"self":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/42562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/comments?post=42562"}],"version-history":[{"count":0,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/posts\/42562\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media\/42563"}],"wp:attachment":[{"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/media?parent=42562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/categories?post=42562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailynewsindia.co.in\/index.php\/wp-json\/wp\/v2\/tags?post=42562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}